[Molecular international prognostic scoring system for myelodysplastic syndromes]

The prognosis for patients with myelodysplastic syndromes (MDS) was classified into several groups by the International Prognostic Scoring System for Myelodysplastic Syndromes (IPSS) or its revised version, based on chromosome aberrations, blast counts, and hematological abnormalities. Although genetic mutations, including TP53, DDX41, and SF3B1, had prognostic importance, the coexistence of these genetic abnormalities makes systematic risk stratification extremely hard. Recently, an international working group reported a large study of 3,000 patients with MDS, which proposed a novel IPSS using genetic mutations (IPSS-M). They have released an open-access web page ( https://mds-risk-model.com/ ) that considers missing values and is being used worldwide. By combining genomic profiling with hematological and cytogenetic parameters, IPSS-M is expected to improve the risk stratification of patients with MDS and be an essential tool for clinical decision-making, including treatment options.